CYTOMED THERAPEUTICS LTD
GDTCNASDAQ🏆 #3783 by market capUS Equity
$534.92▲ $3.37 (+0.63%)
Simulated price1h—
24h▲ 0.6%
7d▲ 60776.3%
14d▲ 72303.9%
30d▲ 54483.7%
1y▲ 29951.7%
🏦Market Cap
$7M
Small Cap
📈Revenue Growth (YoY)
+366.8%
High Growth
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
54
Weak
Trading Snapshot
- Day Range
- $530.05 – $542.13
- 52-Week Range
- —
- Volume
- $2.23B
- Avg Volume
- $1.89B
- Shares Outstanding
- 11.8M
- Next Earnings
- Sep 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $678,512
- Last Q Revenue
- $187,330
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own GDTC
- ✓High-growth profile — revenue up +47.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 50% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$678,512▲ +52.9% YoY
Gross Margin (TTM)
49.8%▲ +0.0% YoY
Operating Income (TTM)
$251,049▲ +52.9% YoY
Free Cash Flow (TTM)
$162,164▲ +52.9% YoY
About CYTOMED THERAPEUTICS LTD
A company profile for CYTOMED THERAPEUTICS LTD isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
54/100
Analyst Price Target
ⓘAverage Target
$687.00
▲ +28.4% Upside
High Target$824.18
Low Target$596.89
Based on 36 analysts
Latest News & Updates
🚀
CNBC·2h ago
CYTOMED THERAPEUTICS LTD tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift GDTC price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
CYTOMED THERAPEUTICS LTD announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.